Business Context and Reporting Period
This Form 8-K is filed by PowerUp Acquisition Corp. (not Aspire Biopharma Holdings, Inc., which is the target of the proposed transaction) on October 9, 2024. The filing reports the entry into a Second Amendment Agreement regarding a proposed Business Combination with Aspire Biopharma, Inc. (a Puerto Rico corporation). The transaction involves a merger where Aspire will become a wholly-owned subsidiary of PowerUp.
Key Financial Metrics
This filing is a current report regarding a material definitive agreement and does not contain audited financial statements, revenue, profit, cash flow, or margin data for either PowerUp or Aspire. No specific debt or liquidity figures are disclosed in this document.
Material Changes and Transaction Updates
- Second Amendment Agreement: On October 9, 2024, the parties agreed to extend the Disclosure Schedule Delivery Date to October 11, 2024.
- Purpose of Extension: The extension allows additional time to complete ongoing due diligence reviews and compile disclosure schedules.
- Previous Amendments: This follows an initial Agreement and Plan of Merger (August 26, 2024) and a prior Amendment Agreement (September 5, 2024) which adjusted merger consideration and equity incentive plan sizes.
Guidance, Outlook, and Risks
The filing contains extensive forward-looking statements regarding the anticipated benefits, timing, and financial condition of the combined company. Management cautions that actual results may differ materially due to various risks, including:
- Failure to complete the Business Combination in a timely manner or at all.
- Failure to satisfy closing conditions, including shareholder approval and regulatory approvals.
- Redemptions by PowerUp public shareholders exceeding anticipated levels.
- Failure to meet Nasdaq initial listing standards post-combination.
- Disruption to Aspire's current operations and business relationships.
- Need for Aspire to raise additional capital, which may not be available on acceptable terms.
- Risks related to product development, commercialization, and intellectual property.
Investor Verification Checklist
- Verify the final terms of the Business Combination in the definitive proxy statement/prospectus (Form S-4) once filed.
- Monitor the status of the Disclosure Schedule Delivery Date (extended to October 11, 2024) and subsequent due diligence progress.
- Review the "Risk Factors" section in the upcoming registration statement for detailed risks regarding Aspire's biopharma pipeline and financial needs.
- Confirm the level of shareholder redemptions expected, as this impacts the post-transaction capital structure.
- Check for any further amendments to the Business Combination Agreement if the October 11 deadline is not met.